Mutation-specific effects of lidocaine in Brugada syndrome

International Journal of Cardiology

Volumn 121, Issue 3, 2007, Pages 249-252

  Clancy, Colleen E ^a   Wehrens, Xander H T ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Molecular Physiology and Biophysics ^*  (United States)

Author keywords

Brugada syndrome; Lidocaine; Local anesthetics; Sodium channel; Sudden cardiac death

Indexed keywords

ANTIARRHYTHMIC AGENT; LIDOCAINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; VOLTAGE GATED SODIUM CHANNEL;

ALPHA CHAIN; ARRHYTHMOGENESIS; BRUGADA SYNDROME; DRUG EFFECT; EDITORIAL; ELECTROCARDIOGRAPHY; GENE; GENE MUTATION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE FIBRILLATION; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SCN5A GENE; SODIUM CURRENT; ST SEGMENT ELEVATION; SUDDEN DEATH;

ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIDOCAINE; MUSCLE PROTEINS; MUTATION, MISSENSE; PHENOTYPE; SODIUM CHANNELS;

EID: 34548815376     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.05.060     Document Type: Editorial

References (28)

1. Brugada J., Brugada R., and Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation 97 5 (1998) 457-460
2. Nademanee K., Veerakul G., Nimmannit S., et al. Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 96 8 (1997) 2595-2600
3. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 9 5 (1998) 513-516
4. Priori S.G., Napolitano C., Schwartz P.J., Bloise R., Crotti L., and Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 102 9 (2000) 945-947
5. Chen Q., Kirsch G.E., Zhang D., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 6673 (1998) 293-296
6. Clancy C.E., and Kass R.S. Defective cardiac ion channels: from mutations to clinical syndromes. J Clin Invest 110 8 (2002) 1075-1077
7. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2 4 (2005) 429-440
8. Wang D.W., Makita N., Kitabatake A., Balser J.R., and George Jr. A.L. Enhanced Na(+) channel intermediate inactivation in Brugada syndrome. Circ Res 87 8 (2000) E37-E43
9. Itoh H., Tsuji K., Sakaguchi T., et al. A paradoxal effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome. Int J Cardiol 121 (2007) 239-248 10.1016/j.ijcard.2007.02.007
10. Itoh H., Shimizu M., Takata S., Mabuchi H., and Imoto K. A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol 16 5 (2005) 486-493
11. Yan G.X., and Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 15 (1999) 1660-1666
12. Zhang Z.S., Tranquillo J., Neplioueva V., Bursac N., and Grant A.O. Sodium channel kinetic changes that produce Brugada syndrome or progressive cardiac conduction system disease. Am J Physiol Heart Circ Physiol 292 1 (2007) H399-H407
13. Liu H., Clancy C., Cormier J., and Kass R. Mutations in cardiac sodium channels: clinical implications. Am J Pharmacogenomics 3 3 (2003) 173-179
14. Strichartz G.R., Sanchez V., Arthur G.R., Chafetz R., and Martin D. Fundamental properties of local anesthetics. II. Measured octanol:buffer partition coefficients and pKa values of clinically used drugs. Anesth Analg 71 2 (1990) 158-170
15. Ragsdale D.S., McPhee J.C., Scheuer T., and Catterall W.A. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci U S A 93 17 (1996) 9270-9275
16. Liu H., Atkins J., and Kass R.S. Common molecular determinants of flecainide and lidocaine block of heart Na+ channels: evidence from experiments with neutral and quaternary flecainide analogues. J Gen Physiol 121 3 (2003) 199-214
17. Kambouris N.G., Hastings L.A., Stepanovic S., Marban E., Tomaselli G.F., and Balser J.R. Mechanistic link between lidocaine block and inactivation probed by outer pore mutations in the rat micro1 skeletal muscle sodium channel. J Physiol 512 Pt 3 (1998) 693-705
18. Armstrong C.M. Sodium channels and gating currents. Physiol Rev 61 3 (1981) 644-683
19. Lipkind G.M., and Fozzard H.A. Molecular modeling of local anesthetic drug binding by voltage-gated sodium channels. Mol Pharmacol 68 6 (2005) 1611-1622
20. Fozzard H.A., Lee P.J., and Lipkind G.M. Mechanism of local anesthetic drug action on voltage-gated sodium channels. Curr Pharm Des 11 21 (2005) 2671-2686
21. Veldkamp M.W., Viswanathan P.C., Bezzina C., Baartscheer A., Wilde A.A., and Balser J.R. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ Res 86 9 (2000) E91-E97
22. Viswanathan P.C., Bezzina C.R., George Jr. A.L., Roden D.M., Wilde A.A., and Balser J.R. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. Circulation 104 10 (2001) 1200-1205
23. Sanguinetti M.C., and Bennett P.B. Antiarrhythmic drug target choices and screening. Circ Res 93 6 (2003) 491-499
24. Bennett P.B., Yazawa K., Makita N., and George Jr. A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 376 6542 (1995) 683-685
25. + channel. Circ Res 88 7 (2001) 740-745
26. Mujtaba M.G., Wang S.Y., and Wang G.K. Prenylamine block of Nav1.5 channel is mediated via a receptor distinct from that of local anesthetics. Mol Pharmacol 62 2 (2002) 415-422
27. + channel levels. Mol Pharmacol 70 5 (2006) 1514-1523
28. + channels as therapeutic targets for antiarrhythmic agents. Handb Exp Pharmacol 171 (2006) 99-121